secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000320017-22-000101
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics Q3 net loss widens to $37.4M on merger costs; cash $75.5M; LSTA1 trials on track
--------------------------------------------------------------------------------

- Net loss $37.4M (Q3 2022) vs $6.9M (Q3 2021), driven by merger-related expenses and stock compensation.
- Cash, equivalents and marketable securities $75.5M as of Sept 30, 2022.
- R&D expenses $3.4M (-18% YoY) due to XOWNA FREEDOM trial suspension; G&A $3.9M (+39%) on merger costs.
- LSTA1 Phase 2b ASCEND and Phase 1b/2 CENDIFOX trials on track to complete enrollment late 2023/early 2024.
- HONEDRA (CLI) pre-consultation with PMDA ongoing; XOWNA (CMD) development paused pending strategic partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000101/0000320017-22-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000101/clbs-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000320017-22-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer